GV20 Therapeutics
- Biotech or pharma, therapeutic R&D
Integrating AI, genomics and cancer biology to harness the power of the human immune system for next-generation antibody therapeutics. Lead program, a first-in-class antibody against novel innate checkpoint IGSF8, is in Ph1 clinical studies in the US.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}